A Multicenter, Clinical Study of FOLFOXIRI With Bevacizumab As First-line Therapy in Patients With mCRC

NCT02246049 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

69

Enrollment

OTHER

Sponsor class

Conditions

Colorectal Neoplasms

Interventions

BIOLOGICAL: Bevacizumab
DRUG: 5-fluorouracil
DRUG: Irinotecan hydrochloride
DRUG: Leucovorin calcium
DRUG: Oxaliplatin

Sponsor

EPS Corporation